Repligen (NASDAQ:RGEN) Cut to “Hold” at Wall Street Zen

Repligen (NASDAQ:RGEN) was downgraded by equities researchers at Wall Street Zen from a “buy” rating to a “hold” rating in a report issued on Saturday.

A number of other analysts also recently issued reports on RGEN. Barclays dropped their target price on shares of Repligen from $200.00 to $175.00 and set an “overweight” rating for the company in a research report on Wednesday. UBS Group dropped their price objective on shares of Repligen from $200.00 to $195.00 and set a “buy” rating for the company in a research report on Wednesday. Wells Fargo & Company cut their target price on shares of Repligen from $190.00 to $180.00 and set an “overweight” rating on the stock in a research note on Wednesday. KeyCorp reaffirmed an “overweight” rating on shares of Repligen in a research report on Wednesday. Finally, Weiss Ratings upgraded Repligen from a “sell (d+)” rating to a “hold (c-)” rating in a report on Tuesday, February 17th. One investment analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating and three have given a Hold rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $174.58.

Repligen Trading Down 3.7%

Shares of RGEN opened at $128.73 on Friday. Repligen has a twelve month low of $102.96 and a twelve month high of $175.77. The firm has a market capitalization of $7.25 billion, a P/E ratio of 151.45, a price-to-earnings-growth ratio of 2.54 and a beta of 1.13. The company has a current ratio of 8.37, a quick ratio of 7.14 and a debt-to-equity ratio of 0.26. The stock’s fifty day simple moving average is $154.18 and its 200 day simple moving average is $146.80.

Repligen (NASDAQ:RGEN) last posted its quarterly earnings results on Tuesday, February 24th. The biotechnology company reported $0.49 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.44 by $0.05. The firm had revenue of $197.91 million during the quarter, compared to the consensus estimate of $192.23 million. Repligen had a return on equity of 4.71% and a net margin of 6.62%.The firm’s quarterly revenue was up 18.1% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.44 earnings per share. Repligen has set its FY 2026 guidance at 1.930-2.010 EPS. On average, equities research analysts forecast that Repligen will post 1.72 earnings per share for the current year.

Insiders Place Their Bets

In related news, Director Karen A. Dawes sold 275 shares of Repligen stock in a transaction on Wednesday, December 17th. The shares were sold at an average price of $161.00, for a total transaction of $44,275.00. Following the sale, the director owned 91,821 shares of the company’s stock, valued at $14,783,181. The trade was a 0.30% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 1.20% of the company’s stock.

Institutional Trading of Repligen

Hedge funds and other institutional investors have recently modified their holdings of the business. Measured Wealth Private Client Group LLC acquired a new position in shares of Repligen in the third quarter worth about $29,000. Bayforest Capital Ltd acquired a new stake in Repligen during the 4th quarter valued at approximately $32,000. Rachor Investment Advisory Services LLC purchased a new stake in Repligen during the 4th quarter worth approximately $33,000. Los Angeles Capital Management LLC acquired a new position in shares of Repligen in the 4th quarter valued at approximately $36,000. Finally, Hantz Financial Services Inc. boosted its stake in shares of Repligen by 2,663.6% during the 2nd quarter. Hantz Financial Services Inc. now owns 304 shares of the biotechnology company’s stock valued at $38,000 after buying an additional 293 shares during the last quarter. 97.64% of the stock is owned by hedge funds and other institutional investors.

About Repligen

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.